Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy-Reference-Cited by-同舟云学术

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy

Published:2003-12 Issue:12 Volume:89 Page:2312-2319
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Atkins H,Davies B R,Kirby J A,Kelly J D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6601474.pdf

Reference36 articles.

1. Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette–Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150: 1932–1937

2. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, Ebner C (1999) Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 29: 2344–2353

3. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Bohle A (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697–702

4. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S (2000) Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165: 6278–6286

5. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186: 1623–1631

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer;Frontiers in Bioscience-Landmark;2024-08-21

2. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer;Journal of Clinical Medicine;2024-03-31

3. Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer;Bioactive Materials;2024-01

4. A candidate prognostic biomarker: TFEB inhibits tumor progression via elevating CDKN1A in bladder cancer;International Immunopharmacology;2023-12

5. Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer;Urology Herald;2022-12-26